# ClinicalTrials.gov record NCT02563353

> PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02563353-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02563353-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02563353-teriparatide-v1.json
- Content SHA-256: `b46723b434eb2cba8f71b7b3beb65d91008c6711ab61bf5146e1a58489779216`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02563353 ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

## Sources

<a id="source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2"></a>
- **ClinicalTrials.gov record NCT02563353 · retained source version 2020-09-18:d2447baecdf25f2c1c72df4c256e7010ea6326ab961dfee3415da7cc41bc23bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02563353) (`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02563353." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02563353-teriparatide-v1.json SHA-256: b46723b434eb2cba8f71b7b3beb65d91008c6711ab61bf5146e1a58489779216.